Challenge:

The National Cancer Institute (NCI) faces a complex challenge in managing cancer clinical trials across more than 2,000 sites in the U.S. and internationally. Coordinating research, ensuring patient safety, sharing adverse event data, and streamlining regulatory processes are critical to advancing cancer therapies. Without an efficient and user-friendly IT platform, researchers would experience delays in trial design, protocol agreements, and data sharing, ultimately slowing the approval of new cancer treatments and therapies. The NCI needed a secure, scalable IT solution to support the Cancer Therapy Evaluation Program (CTEP) and the larger Cancer Trial Network.

Solution:

For over 25 years, CTIS has been the leading provider of information technology services to the NCI’s CTEP-ESYS, the backbone of its Cancer Trial Network. CTIS developed and maintained over 25 software solutions that enable seamless collaboration among cancer researchers, allowing them to work on shared clinical trial protocols more efficiently. These solutions facilitate faster design and approval processes by providing a platform for real-time collaboration. CTIS also developed systems to share adverse event data securely across trial sites and with the FDA, ensuring that medical monitors and regulatory officials can make timely decisions about patient safety.
CTIS’s technology ensures that trial data is protected, particularly safeguarding patient information. Their comprehensive IT services, including software maintenance and development, play a crucial role in managing clinical trial activities and expediting the creation of New Drug Applications (NDAs) for drug approval.

Impact:

CTIS’s long-term support of CTEP-ESYS has significantly accelerated the pace of cancer clinical trials, leading to faster drug approvals and quicker access to life-saving treatments for patients. Their solutions have improved collaboration across research sites, saved time in trial design, and enhanced patient safety through the timely sharing of adverse event data. As a result, CTIS has played a vital role in advancing cancer research and improving health outcomes. In 2022, CTIS received a $100 million contract under CIO-SP3 to continue supporting the program for another five years, demonstrating the sustained value and impact of their work.